TG Therapeutics(US:TGTX) ZACKS·2025-09-03 16:36Core Insights - TG Therapeutics reported a significant earnings miss for Q2 2025, with earnings of 17 cents per share compared to the Zacks Consensus Estimate of 32 cents, although revenues increased by nearly 92% year over year to $141.1 million, driven by strong demand for Briumvi [2][4] Financial Performance - Briumvi's net product sales reached $138.8 million in the U.S. for Q2 2025, marking a 91% year-over-year increase and a 16% sequential increase [4] - Total revenues included $2.3 million from license, milestone, royalty, and other revenues, up from $0.9 million in the same quarter last year [4] - Research and development expenses rose approximately 83.3% year over year to $27.5 million, primarily due to increased manufacturing costs for Briumvi's subcutaneous formulation [5] - Selling, general, and administrative expenses totaled $43.5 million, up nearly 36.8% from the previous year, attributed to higher commercialization costs for Briumvi [5] - As of June 30, 2025, TG Therapeutics had cash and investments totaling $278.9 million, slightly up from $276.2 million at the end of Q1 2025 [6] Guidance and Estimates - The company raised its full-year revenue guidance for 2025 to approximately $585 million, up from the previous estimate of $575 million, with net product sales of Briumvi expected to be between $570 million and $575 million in the U.S. [7] - Operating expenses for the full year are projected to remain around $300 million, unchanged from prior guidance [8] - Following the earnings release, there has been a downward trend in fresh estimates, with the consensus estimate shifting down by 5.38% [9] Stock Performance and Outlook - TG Therapeutics currently holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return in the coming months [11] - The company has a strong Growth Score of A but is lagging in Momentum with a score of F, resulting in an overall VGM Score of D [10]